affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli
Company profile
Ticker
AFMD
Exchange
Website
CEO
Adi Hoess
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Affimed Therapeutics B.V.
SEC CIK
AFMD stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
11 Mar 24
6-K
Affimed Announces 1-for-10 Reverse Stock Split
6 Mar 24
6-K
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype
8 Jan 24
6-K
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
8 Jan 24
6-K
Affimed Announces Positive Data for AFM24 in Combination with the PD-L1
11 Dec 23
6-K
Current report (foreign)
30 Nov 23
6-K
Unaudited consolidated interim statements of comprehensive loss
14 Nov 23
6-K
Affimed Announces Listing Transfer to NASDAQ Capital Markets
4 Oct 23
6-K
Unaudited consolidated interim statements of comprehensive loss
10 Aug 23
6-K
Affimed Announces Addition of Dr. Constanze Ulmer-Eilfort to its Supervisory Board
22 Jun 23
Transcripts
AFMD
Earnings call transcript
2023 Q3
14 Nov 23
AFMD
Earnings call transcript
2023 Q2
10 Aug 23
AFMD
Earnings call transcript
2023 Q1
23 May 23
AFMD
Earnings call transcript
2022 Q4
23 Mar 23
AFMD
Earnings call transcript
2022 Q3
15 Nov 22
AFMD
Earnings call transcript
2022 Q2
11 Aug 22
AFMD
Earnings call transcript
2022 Q1
1 Jun 22
AFMD
Earnings call transcript
2021 Q4
31 Mar 22
AFMD
Earnings call transcript
2021 Q2
8 Sep 21
AFMD
Earnings call transcript
2021 Q1
1 Jul 21
Latest ownership filings
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 24
SC 13G/A
683 Capital Management, LLC
13 Feb 24
SC 13G/A
BlackRock Inc.
7 Jul 23
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 23
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 23
SC 13G/A
683 Capital Management, LLC
14 Feb 23
SC 13G/A
Ridgeback Capital Investments L.P.
14 Feb 23
SC 13G
BlackRock Inc.
3 Feb 23
SC 13G
BlackRock Inc.
9 May 22
SC 13G
Gilde Healthcare Holding B.V.
21 Apr 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
36.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 63 |
Opened positions | 2 |
Closed positions | 21 |
Increased positions | 9 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 18.99 bn |
Total shares | 54.81 mm |
Total puts | 2.20 k |
Total calls | 9.80 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
683 Capital Management | 8.23 mm | $3.93 bn |
Gilde Healthcare Holding B.V. | 8.13 mm | $32.09 mm |
SGR Sagittarius Holding | 4.59 mm | $19.15 mm |
Baker Bros. Advisors | 4.45 mm | $2.13 bn |
NEA Management | 4.43 mm | $2.12 bn |
Point72 Asset Management | 4.23 mm | $2.02 bn |
Millennium Management | 3.09 mm | $1.48 bn |
Integrated Core Strategies | 2.26 mm | $13.13 mm |
Eversept Partners | 1.68 mm | $801.29 mm |
FMR | 1.45 mm | $692.11 mm |
News
Affimed Q4 EPS $(1.50) Beats $(1.67) Estimate, Sales $444.55K Miss $1.70M Estimate
28 Mar 24
Earnings Scheduled For March 28, 2024
28 Mar 24
A Preview Of Affimed's Earnings
27 Mar 24
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
6 Mar 24
Affimed Announces 1-for-10 Reverse Stock Split
6 Mar 24
Press releases
Affimed Reports 2023 Financial Results and Operational Progress
28 Mar 24
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024
21 Mar 24
Affimed Announces 1-for-10 Reverse Stock Split
6 Mar 24
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer
8 Jan 24
Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck
3 Jan 24